• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

III期多发性骨髓瘤临床试验的随访持续时间：一项系统评价。

Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review.

作者信息

Ali Mohammad O, Abdullah Hafez M, Obeidat Khaldun, Chakraborty Rajshekhar, Al Hadidi Samer

机构信息

Department of Internal Medicine Sanford School of Medicine University of South Dakota Sioux Falls South Dakota USA.

Department of Internal Medicine John H Stroger Jr Hospital of Cook County Chicago Illinois USA.

出版信息

EJHaem. 2023 Jun 29;4(3):719-722. doi: 10.1002/jha2.680. eCollection 2023 Aug.

DOI:10.1002/jha2.680
PMID:37601879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10435726/
Abstract

Long-term follow-up of multiple myeloma (MM) clinical trials are needed to assess long-term outcomes. We aimed to investigate the length of follow-up of all phase III MM clinical trials. Median follow-up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow-up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long-term clinical trials follow-up and/or publication of results of updated results.

摘要

需要对多发性骨髓瘤（MM）临床试验进行长期随访以评估长期结果。我们旨在调查所有III期MM临床试验的随访时长。新诊断MM临床试验的中位随访持续时间与复发/难治性MM临床试验相比更长（分别为42.7个月和20.5个月）。与当前时代改善的结果相比，MM中III期临床试验的随访持续时间相对较短。应努力促进长期临床试验随访和/或更新结果的发表。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9344/10435726/9c68359df5dc/JHA2-4-719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9344/10435726/9c68359df5dc/JHA2-4-719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9344/10435726/9c68359df5dc/JHA2-4-719-g001.jpg

相似文献

1
Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review.III期多发性骨髓瘤临床试验的随访持续时间：一项系统评价。
EJHaem. 2023 Jun 29;4(3):719-722. doi: 10.1002/jha2.680. eCollection 2023 Aug.
2
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗：当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
3
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.来那度胺联合地塞米松用于复发或难治性多发性骨髓瘤患者的MM - 009和MM - 010 III期试验的总生存期长期随访
Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147. Epub 2009 Jul 23.
4
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
5
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.卡非佐米、地塞米松和达雷妥尤单抗与卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（CANDOR）：一项随机、多中心、开放标签、3 期研究的更新结果。
Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3.
6
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.细胞遗传学对复发性多发性骨髓瘤患者缓解持续时间和总生存期的影响（BSBMT/UKMF 骨髓瘤 X 复发[强化]的长期随访结果）：一项随机、开放标签、3 期试验。
Br J Haematol. 2019 May;185(3):450-467. doi: 10.1111/bjh.15782. Epub 2019 Feb 6.
7
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.帕比司他联合硼替佐米和地塞米松对比硼替佐米和地塞米松联合安慰剂治疗复发或复发难治性多发性骨髓瘤患者：一项多中心、随机、双盲的 3 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
8
Exercise-based cardiac rehabilitation for coronary heart disease.基于运动的冠心病心脏康复。
Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4.
9
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.皮下注射达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（APOLLO）：一项开放标签、随机、多中心、3 期临床试验的随访扩展。
Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.
10
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.

引用本文的文献

1
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.早期全治疗方案治疗的多发性骨髓瘤患者的长期随访：三项临床试验的二次分析
JAMA Oncol. 2025 Jun 5. doi: 10.1001/jamaoncol.2025.1394.
2
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.全疗法IV的长期随访：一项针对标危多发性骨髓瘤的3期临床试验。
Blood Adv. 2025 Feb 25;9(4):950-953. doi: 10.1182/bloodadvances.2024014889.
3
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.

本文引用的文献

1
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.在先前治疗过的多发性骨髓瘤（CASTOR）中，用达雷妥尤单抗、硼替佐米和地塞米松治疗的总生存期：一项随机、开放标签、III 期试验。
J Clin Oncol. 2023 Mar 10;41(8):1600-1609. doi: 10.1200/JCO.21.02734. Epub 2022 Nov 22.
2
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).SWOG S0777 随机 III 期试验的长期随访：硼替佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗未经治疗的多发性骨髓瘤且无立即进行自体干细胞移植（ASCT）意向的患者。
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
3
VRD 方案在多发性骨髓瘤中维持治疗 3 年：总治疗 IIIB 的 15 年随访结果。
Blood Adv. 2024 Feb 13;8(3):703-707. doi: 10.1182/bloodadvances.2023011601.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
4
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.硼替佐米、来那度胺和地塞米松诱导治疗及适应性维持治疗新诊断多发性骨髓瘤的长期随访结果。
J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16.
5
Assessment of Long-term Follow-up of Randomized Trial Participants by Linkage to Routinely Collected Data: A Scoping Review and Analysis.通过与常规收集数据的链接评估随机试验参与者的长期随访：范围综述和分析。
JAMA Netw Open. 2018 Dec 7;1(8):e186019. doi: 10.1001/jamanetworkopen.2018.6019.
6
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.近十年多发性骨髓瘤患者的生存率显著提高：一项基于瑞典人群研究的结果
Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22.
7
Liberating the data from clinical trials.从临床试验中解放数据。
BMJ. 2015 Sep 16;351:h4601. doi: 10.1136/bmj.h4601.
8
E-health data to support and enhance randomised controlled trials in the United Kingdom.支持并加强英国随机对照试验的电子健康数据。
Clin Trials. 2015 Apr;12(2):180-2. doi: 10.1177/1740774514562030. Epub 2014 Dec 5.
9
Curing myeloma at last: defining criteria and providing the evidence.最终治愈骨髓瘤：界定标准并提供证据。
Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.
10
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.一项比较全乳切除术、乳房肿瘤切除术以及乳房肿瘤切除术加放疗治疗浸润性乳腺癌的随机试验的20年随访。
N Engl J Med. 2002 Oct 17;347(16):1233-41. doi: 10.1056/NEJMoa022152.